Full Press Release Details
Tiziana Life Sciences Announces
Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
NEW YORK, August 23 2023 -- Tiziana
Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough
immunomodulation therapies via novel routes of drug delivery, today announced an oral presentation of "Nasal anti-CD3 mAb induces
Tregs that dampen microglial activation and treat neuroinflammatory diseases including MS, AD and ALS" at the 16th International
Society of Neuroimmunology (ISNI) Congress in Quebec City, Canada, being held August 21-24, 2023. Dr. Weiner's live presentation
is scheduled for 11:42 a.m. ET on August 24, 2023.
"We are expanding our
understanding of foralumab through rigorous research1 and clinical trials designed
to study this potential treatment for neuroinflammatory diseases," said Howard L. Weiner, MD, Chairman of Tiziana's Scientific
Advisory Board. Dr. Weiner is also co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a
founding member of Mass General Brigham healthcare system.
"Dr. Weiner's presentation on
foralumab, or nasal anti-CD3 mAb will also include updates on our Multiple Sclerosis Expanded Access (EA) program", commented Gabriele
Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana. "I am truly excited at the rapid progress
of our foralumab program. This quarter, we have successfully filed our Alzheimer's IND and received a "may proceed"
FDA response. In addition, we will conduct our multiple sclerosis Phase 2a investigator's meeting, announce our 6-month clinical
findings and PET scans for EA Patients 3 through 6 and lastly enroll EA patients 7 through 10."
About the ISNI Annual Congress
The 16th ISNI Congress focuses
on the latest fundamental, clinical, and technological advances in neuroimmunology. Topics include not only neuroimmune diseases, such
as multiple sclerosis, but also neurodegenerative disorders involving inflammatory processes, such as Alzheimer's disease, stroke,
spinal cord injury, and brain cancer.
Activated T cells play an important role
in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens
inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been
demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials
are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents
a novel avenue for treatment of inflammatory human diseases.1
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company
developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's
innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous
(IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated
a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of
immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor